Search
Lysergic acid 2,4-dimethylazetidide
go.drugbank.com/drugs/DB15196ExperimentalLysergic acid 2,4-dimethylazetidide is under investigation in clinical trial NCT02765802 (A Study to Evaluate Pegylated Interferon Lambda Monotherapy in Patients With Chronic Hepatitis Delta Virus Infection
Ciraparantag
go.drugbank.com/drugs/DB15199InvestigationalCiraparantag is under investigation in clinical trial NCT01826266 (Effects of a Double-Blind, Single Dose of PER977 Administered Alone, and Following a Single Dose of Edoxaban).
JNJ-26489112
go.drugbank.com/drugs/DB15203InvestigationalJNJ-26489112 is under investigation in clinical trial NCT00579384 (A Study of the Effects of JNJ-26489112 on the Photic Induced Paroxysmal Electroencephalogram (EEG) Response in Patients With Photosensitive
Pemafibrate
go.drugbank.com/drugs/DB15212InvestigationalPemafibrate is under investigation in clinical trial NCT03350165 (A Study of Pemafibrate in Patients With Nonalcoholic Fatty Liver Disease (NAFLD)).
Semorinemab
go.drugbank.com/drugs/DB15234InvestigationalSemorinemab is under investigation in clinical trial NCT03289143 (A Study to Evaluate the Efficacy and Safety of RO7105705 in Patients With Prodromal to Mild Alzheimer's Disease).
Olinciguat
go.drugbank.com/drugs/DB15238InvestigationalOlinciguat is under investigation in clinical trial NCT03892499 (A Trial to Evaluate the Effect of Itraconazole (ITZ), a CYP3A4 Inhibitor, on the Pharmacokinetics of the Soluble Guanylate Cyclase Stimulator
Reldesemtiv
go.drugbank.com/drugs/DB15256InvestigationalReldesemtiv is under investigation in clinical trial NCT03160898 (A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)).
Tovorafenib
go.drugbank.com/drugs/DB15266ApprovedInvestigationalTovorafenib is a selective type II RAF kinase inhibitor with anti-tumour activity. … [A263597] It was granted accelerated approval by the FDA, making it the first FDA approval of a systemic therapy for the treatment of pediatric low-grade glioma, with BRAF rearrangements.
Inavolisib
go.drugbank.com/drugs/DB15275ApprovedInvestigational_PIK3CA_ is one of the most frequently mutated oncogenes, with the resulting mutated p110α protein it encodes playing a central role in tumor cell proliferation. … [A264563] Chemotherapeutic agents targeting the PI3K p110α catalytic subunit have shown antitumor activity and a manageable safety profile - some of which are in clinical use, like [alpelisib] - but preclinical
Gedivumab
go.drugbank.com/drugs/DB15277InvestigationalGedivumab is under investigation in clinical trial NCT01877785 (A Study of MHAA4549A to Assess Safety And Pharmacokinetics in Healthy Volunteers).